AI-generated analysis. Always verify with the original filing.
Palvella Therapeutics filed an 8-K on March 31, 2026 disclosing 2025 full-year financial results and key corporate and pipeline updates for investors.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, an
Financial Statements and Exhibits. ## (d) Exhibits | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release of Palvella Therapeutics, Inc., dated